Maintenance of cAMP in non-heart-beating donor lungs reduces ischemia-reperfusion injury

American Journal of Respiratory and Critical Care Medicine

Volumn 163, Issue 7, 2001, Pages 1642-1647

  Hoffmann, Steven C ^a   Bleiweis, Mark S ^a   Jones, David R ^a   Paik, Hyo Chae ^a   Ciriaco, Paola ^a   Egan, Thomas M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE; CYCLIC AMP; ISOPRENALINE; ROLIPRAM;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY PERMEABILITY; CELL VIABILITY; HEART ARREST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISCHEMIA; LUNG CAPILLARY; LUNG HEMODYNAMICS; LUNG PERFUSION; LUNG TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; REPERFUSION INJURY;

EID: 0034954273     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.163.7.9911060     Document Type: Article

References (30)

1. A strategy to increase the donor pool: The use of cadaver lungs for transplantation
2. When does the lung die? Time course of high energy phosphate depletion and relationship to lung viability after "death"
3. When does the lung die? II. Ultrastructural evidence of pulmonary viability after "death"
4. When does the lung die? - Kfc, cell viability, and adenine nucleotide changes in the circulation-arrested rat lung
5. Pharmacological modification of pulmonary vascular injury: Possible role of cAMP
6. Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels
7. Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties
8. Rolipram and isoproterenol reverse platelet activating factor-induced increases in pulmonary microvascular permeability and vascular resistance
9. Adenosine 3′5′-cyclic monophosphate attenuates neutrophil-mediated increase in endothelial permeability
10. Compounds that increase cAMP prevent ischemia-reperfusion pulmonary capillary injury
11. Reversal of increased microvascular permeability associated with ischemia-reperfusion: Role of cAMP
12. Protamine-induced acute lung injury and the protective effect of agents that increase cAMP
13. Amelioration of reperfusion injury by pentoxifylline after lung transplantation
14. Elevation of intracellular cAMP by a phosphodiesterase inhibitor or cAMP analogs improves vascular function in orthotopic rat lung transplants
15. Reduced ischemia-reperfusion injury with isoproterenol in non-heart-beating donor lungs
16. Reduced ischemia-reperfusion injury with rolipram in rat cadaver lung donors: Effect of cAMP?
17. Pulmonary capillary pressure and filtration coefficient in the isolated perfused lung
18. Activated eosinophils increase vascular permeability and resistance in isolated perfused rat lungs
19. U74500A inhibition of oxidant-mediated lung injury
20. Is pulmonary microvascular integrity maintained after death?
21. Validation of double vascular occlusion method for Pc,i in lung and skeletal muscle
22. Filtration, diffusion and molecular sieving through the peripheral capillary membranes: A contribution to the pore theory of capillary permeability
23. Dye exclusion tests for cell viability
24. In vitro carcinogenesis studies with human tracheobronchial tissues and cells
25. Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor
26. When does the lung die? I. Histochemical evidence of pulmonary viability after "death"
27. Contractile proteins of endothelial cells, platelets and smooth muscle
28. Role of endothelial cell cytoskeleton in control of endothelial permeability
29. Hypoxia and modification of the endothelium: Implications for regulation of vascular homeostatic properties
30. Tumor necrosis factor-α in ischemia and reperfusion injury in rat lungs